A new hemophilia treatment has just been approved by the FDA, and it has its roots in the Philadelphia region.
The drug is called Obizur, and much of its development was done by Octagen, a Bala Cynwyd, Pa. biotechnology company. The drug is now owned by Baxter International.
Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder that, unlike congenital hemophilia, typically affects older adults. It occurs equally in both males and females.
For more business stories, head to PBJ.com
Copyright bizjournal